System and method for diagnosing and treating a disease using electromagnetic energy

Abstract

The present disclosure provides a system for providing a therapeutic effect to a subject, comprising: at least one energy application unit, configured to emit one of a low- frequency electromagnetic (LFEM) radiation or a low-frequency magnetic field (LFMF); and a controller configured to: receive one or more LFEM waveforms or one or more FEME waveforms that correspond to a reference treatment; and control the at least one energy application unit to emit the one or more LFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment. The system may further include an LFEM sensor or LFMF sensor. The controller may compare an endogenous signal from the subject with the received waveforms.

Description

SYSTEM AND METHOD FOR DIAGNOSING AND TREATING A DISEASE USING ELECTROMAGNETIC ENERGYCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of U.S. Provisional Patent Applications No. 63 / 661,889, titled " SYSTEM AND METHOD FOR DIAGNOSING AND TREATING A DISEASE USING ELECTROMAGNETIC ENERGY", filed 20 June 2024, the contents of which are all incorporated herein by reference in their entirety.FIELD OF THE INVENTION

[0002] The present invention relates generally to methods for diagnosing and treating a disease. More specifically, the present invention relates to a method for treating a medical condition using low-frequency electromagnetic fields (EMF) or low-frequency magnetic fields radiation.BACKGROUND OF THE INVENTION

[0003] Low frequency electromagnetic fields (EMF) up to 200 MHz have been utilized in various medical applications for diagnosis and therapy. Three main EMF applications in medicine are magnetic resonance imaging (MRI), radiofrequency ablation (RFA), and localized dielectric heating (short wave diathermy).

[0004] MRI employs three different fields to generate images: a static magnetic field, low power time-varying magnetic field gradients, and radiofrequency fields. RFA is used in cardiology and tumor therapy to destroy unhealthy tissue through thermal effects.

[0005] Recent developments have introduced new methods of using EMF as a diagnostic tool. For example, arrays of ultrasensitive magnetic sensors capable of measurements at the pico-tesla level have been employed to detect weak biometric EMF. These sensors can be arranged to detect biomagnetism over large areas of the body, such as the chest for cardiac modeling.

[0006] While EMF-based medical technologies have shown effectiveness in various applications, there remains room for improvement in utilizing EMF for both diagnosis and treatment . Additionally, the potential for using low-frequency EMF signals for therapeutic purposes has not been fully explored.

[0007] Current EMF-based diagnostic and treatment methods often focus on specific frequency ranges or applications. However, a more comprehensive approach that integrates diagnosis and treatment using a wider spectrum of EMF frequencies could potentially offer additional benefits in managing various medical conditions.

[0008] Furthermore, existing EMF therapies typically employ standardized protocols that may not account for individual variations in patient physiology or response to treatment. A more personalized approach to EMF-based diagnosis and therapy could potentially enhance treatment outcomes.

[0009] As medical technology continues to advance, there is an ongoing need for innovative approaches that can leverage the diagnostic and therapeutic potential of electromagnetic fields across a broader range of applications and with greater precision.SUMMARY OF THE INVENTION

[0010] According to an aspect of the present disclosure, a system for providing a therapeutic effect to a subject is provided. The system includes at least one energy application unit, configured to emit a low-frequency electromagnetic (LFEM) radiation or configured to emit a low-frequency magnetic field (LFMF). The system may also include a controller configured to receive one or more LFEM waveforms or one or more LFMF waveforms that correspond to a reference treatment, and control the at least one energy application unit to emit the one or more LFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment.

[0011] In some embodiments, the system may further include an LFEM sensor or LFMF sensor. The controller may further be configured to receive one or more LFEMwaveforms or LFMF waveforms that correspond to the reference treatment. In some embodiments, the controller may further be configured to compare an endogenous signal from the subject with the received one or more LFEM waveforms or LFMF waveforms, and may control the at least one energy application unit by driving the energy-application unit to emit one or more therapeutic LFEM waveforms or LFMF waveforms derived from the one or more received LFEM waveforms or LFMF waveforms so as to achieve a desired therapeutic effect. The reference treatment may be selected, for example, from: an administration of a pharmacologic agent, a physicaldevice therapy, a psychiatric, neurological, oncological, behavioral or psychologic, oncological, inflammatory, allergic intervention, and a metabolic, geroprotective / longevity, or anti-obesity intervention.

[0012] In some embodiments, the pharmacologic agent may be selected from the group consisting of: (i) an insulin or insulin analogue; (ii) a glucagon-like peptide- 1 (GLP-1) receptor agonist; (iii) a sodium-glucose co-transporter-2 (SGLT-2) inhibitor; (iv) a P-adrenergic antagonist; (v) a serotonergic or dopaminergic neuromodulator; (vi) a cytotoxic or targeted chemotherapeutic compound; (vii) an agent that enhances mitochondrial function or biogenesis, selected from NAD+precursors, sirtuin activators, pyrroloquinoline quinone (PQQ), coenzyme Q10, or a PGC- la up-regulator; (viii) an mTOR-pathway modulator or AMPK activator, including rapamycin, metformin, or analogues thereof; and any pharmaceutically acceptable combinations thereof. The LFEM radiation or LFMF radiation may have a frequency ranging between 0.1 to 100 Hz. The LFEM radiation or LFMF radiation may have a nonharmonic frequency waveform. The LFEM radiation or LFMF radiation may have a root-mean- square magnetic-flux density in the range of 0.1 pT to 10 pT. The at least one energy application unit may comprise an LFEM radiation generator and at least one LFEM radiation antenna. The at least one energy application unit may comprise a power source and at least one magnetic coil.

[0013] According to another aspect of the present disclosure, a method for providing a therapeutic effect to a subject is provided. The method includes receiving one or more low-frequency electromagnetic (LFEM) waveforms or one or more low- frequency magnetic field (LFMF) waveforms, that correspond to a reference treatment, and controlling at least one energy application unit to emit the one or more LFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment.

[0014] According to other aspects of the present disclosure, the method may include one or more of the following features. The method may further comprise receiving from an LFEM sensor or LFMF sensor one or more LFEM waveforms or LFMF waveforms that correspond to the reference treatment. The method may further comprise comparing an endogenous signal from the subject with the received one or more LFEM waveforms or LFMF waveforms, and wherein controlling the at least one energy application unit may comprise driving the energy application unit to emit one or more therapeutic LFEM waveforms or LFMF waveforms derived from the one or more received LFEM waveforms or LFMF waveforms so as to achieve a desired therapeutic effect. The reference treatment may be selected from: an administration of a pharmacologic agent, a physical-device therapy, a psychiatric, neurological, behavioral or psychologic, oncological, inflammatory, allergic intervention, and a metabolic, geroprotective / longevity, or anti-obesity intervention. The pharmacologic agent may be selected from the group consisting of: (i) an insulin or insulin analogue; (ii) a glucagon-like peptide- 1 (GLP-1) receptor agonist; (iii) a sodium-glucose cotransporter-2 (SGLT-2) inhibitor; (iv) a P-adrenergic antagonist; (v) a serotonergic or dopaminergic neuromodulator; (vi) a cytotoxic or targeted chemotherapeutic compound; (vii) an agent that enhances mitochondrial function or biogenesis, selected from NAD+precursors, sirtuin activators, pyrroloquinoline quinone (PQQ), coenzyme Q10, or a PGC-la up-regulator; (viii) an mTOR-pathway modulator or AMPKactivator, including rapamycin, metformin, or analogues thereof; and any pharmaceutically acceptable combinations thereof.

[0015] According to another aspect of the present disclosure, a system for producing a desired therapeutic effect in a subject is provided. The system includes at least one energy-application unit configured to emit low-frequency electromagnetic radiation (LFEM) or configured to emit a low-frequency magnetic field (LFMF), and a controller configured to receive a reference LFEM or LFMF waveform that corresponds to a reference treatment, and drive the energy-application unit to emit a therapeutic waveform derived from the reference waveform so as to achieve the desired therapeutic effect.

[0016] In some embodiments, the system may include one or more of the following features. The controller may be further configured to compare an endogenous signal from the subject with the reference waveform. The endogenous signal may be received from at least one of: Continuous Glucose Monitoring (CGM), pulse oximetry, heart rate monitoring, blood pressure monitoring, electroencephalography (EEG), electromyography (EMG), temperature sensing, cortisol sensing, lactate sensing, and pH sensing. The reference treatment may be selected from: an administration of a pharmacologic agent, a physical-device therapy, a psychiatric, neurological, behavioral, or psychologic, oncological, inflammatory, allergic intervention, and a metabolic, geroprotective / longevity, or anti-obesity intervention.

[0017] According to another aspect of the present disclosure, a non-transitory computer readable storage medium storing a set of instructions for causing a computer to receive one or more LFEM waveforms or one or more FLMF waveforms that correspond to a reference treatment, and control at least one energy application unit to emit the one or more LFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment is provided.

[0018] Some aspects of the invention are directed to a method for treating diagnosing and / or treating subject, comprising: measuring a first (electromagnetic) EM field of atleast one of: a subject, an organ of the subject, a tissue, and a cell; receiving at least one previously recorded EM field, associated with a healthy state of: the subject, the organ of the subject, the tissue and / or the cell; detecting a change in at least one parameter between the measured EM field and the received EM field; and if the change is different from (e.g., greater than) a threshold value, irradiating the at least one of: the subject, the organ of the subject, the tissue, and the cell with EM radiation that causes a measured second EM field, measured after the irradiation to be an EM field associated with the healthy state or one that results in desired physiological effect.

[0019] In some embodiments, measuring the EM field of the subject comprises: placing an array of ultrasensitive magnetic sensors in proximity to the subject, the organ of the subject, the tissue and / or the cell; and receiving EMF measurements from the array. In some embodiments, irradiating the subject includes placing an array of EMF antennas in a predetermined distance from the subject; and generating EM energy to be emitted from the array of EMF antennas.

[0020] In some embodiments, irradiating the organ of the subject includes placing an array of RF electrodes on at least one of: a skin of the subject, the organ of the subject and the tissue. In some embodiments, measuring the EM field comprises measuring waveforms and intensities of the EM field. In some embodiments, detecting the change comprises detecting a change in at least one waveform and intensity. In some embodiments, detecting the change comprises detecting a change in a pattern of the measured EM field. In some embodiments, the method further comprises, receiving feedback from at least one sensor indicating where a sufficient in the medical condition is achieved and determine the irradiation parameters of the EM radiation based on the received feedback.

[0021] Some aspects of the invention are directed to a system for treating a subject, comprising: one or more EM field sensors; one or more EM wave generators; and a computing device configured to: receive from the one or more EM sensors measured first EM field of at least one of: a subject, an organ of the subject, a tissue, and a cell; receiveat least one previously recorded EM field, associated with a healthy state of: the subject, the organ of the subject, the tissue and / or the cell; detect a change in at least one parameter between the measured EM field and the received EM field; and if the change is different from (e.g., greater than) a threshold value, irradiate, using the one or more EM wave generators, the at least one of: the subject, the organ of the subject, the tissue, and the cell with EM radiation that causes a measured second EM field, measured after the irradiation to be an EM field associated with the healthy state.BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings in which:

[0023] Fig. 1 is a block diagram, depicting a system for treating a disease according to some embodiments of the invention;

[0024] Fig. 2 is a block diagram, depicting a computing device which may be included in a system for treating a disease according to some embodiments;

[0025] Fig. 3 is a flowchart of a method of treating a medical condition according to some embodiments;

[0026] Fig. 4 is a flowchart of a method of providing a therapeutic effect to a subject, according to some embodiments;

[0027] Fig. 5 is a flowchart of another method of providing a therapeutic effect to a subject according to some embodiments;

[0028] Fig. 6A is a graph of low-frequency magnetic field (LFMF) waveform during the provision of 1 unit of insulin and 2 units of insulin according to some embodiments of the invention;

[0029] Fig. 6B is an image of a LFMF device comprising a coil that allows to treat a subject with a desired LFMF waveform according to some embodiments of the invention; and

[0030] Figs. 7A and 7B, which show real glucose measurements taken from Continuous Glucose Monitoring (CGM) during the provision of LFMF waveform to a diabetic subject, and a control measurement, respectively, according to some embodiments of the invention.

[0031] It will be appreciated that for simplicity and clarity of illustration, elements shown in the figures have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity. Further, where considered appropriate, reference numerals may be repeated among the figures to indicate corresponding or analogous elements.DETAILED DESCRIPTION OF THE PRESENT INVENTION

[0032] One skilled in the art will realize the invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the invention described herein. Scope of the invention is thus indicated by the appended claims, rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

[0033] In some embodiments, the system may utilize electromagnetic field (EMF) technology for diagnostic and therapeutic purposes. This approach may offer potential benefits such as non-invasive monitoring and treatment of various medical conditions.

[0034] The present invention addresses several challenges in modem medical treatment and offers innovative solutions through the use of electromagnetic field (EMF) technology.

[0035] Conventional medical treatments often involve the administration of pharmacological agents, physical therapies, or invasive procedures. While these approaches can be effective, they may also come with limitations such as side effects, the need for frequent dosing, invasiveness, or high costs. Additionally, some patients may develop tolerance to certain medications over time, reducing their efficacy.

[0036] The present invention aims to overcome these limitations by providing a system and method that can replace or supplement conventional treatments with EMF- based therapies. This approach is based on the discovery that specific EMF waveforms can mimic the physiological effects of various conventional treatments.

[0037] The core concept of this invention may involve recording the EMF effects produced during the administration of conventional treatments, such as pharmacological agents or physical therapies. These recorded EMF waveforms may serve as a reference for the therapeutic effect. The system then may generate and applies similar EMF waveforms to achieve comparable therapeutic outcomes without the need for the original treatment modality.

[0038] This EMF-based approach may offer several potential advantages:1. Non- invasiveness: The treatment may be administered externally, reducing the need for invasive procedures or drug administration.2. Reduced side effects: By mimicking only the beneficial EMF effects of a treatment, the system may potentially avoid some of the side effects associated with conventional therapies.3. Customization: The system may allow for precise control and adjustment of the EMF waveforms, enabling personalized treatment protocols.4. Continuous monitoring and adaptation: By incorporating feedback from EMF sensors and other physiological monitors, the system may adjust the treatment in realtime for optimal efficacy.5. Potential for treating multiple conditions: A single system may potentially be programmed to mimic various treatments for different medical conditions.6. Improved patient compliance: The non-invasive nature of the treatment may lead to better patient adherence to therapy regimens.

[0039] The invention provides a comprehensive solution that includes methods for recording reference EMF waveforms, storing and analyzing these waveforms, generating therapeutic EMF emissions based on the reference waveforms, and monitoring the effects of the treatment. This integrated approach allows for a novel paradigm in medical treatment, where the beneficial effects of conventional therapies can be reproduced using controlled electromagnetic fields.

[0040] The system may incorporate an array of ultrasensitive magnetic sensors to measure electromagnetic fields associated with a subject, organ, tissue, or cell. These sensors may be capable of detecting subtle changes in EMF waveforms and intensities. In some cases, the measured EMF data may be compared to reference EMF profiles corresponding to healthy states or specific medical conditions.

[0041] In some embodiments, the system may include EMF emitting components for therapeutic applications. An array of EMF antennas may be positioned at a predetermined distance from the subject to deliver electromagnetic radiation. Alternatively or additionally, an array of RF electrodes may be placed in contact with the skin, organ, or tissue of the subject to provide localized EMF exposure.

[0042] The system may employ a feedback mechanism to optimize treatment parameters. Sensors may continuously monitor the subject's EMF and physiological responses during EMF application. This feedback data may be analyzed to determine appropriate adjustments to the irradiation parameters such as frequency, intensity, waveform shape, or duration. The EMF emission may be modulated in real-time based on this feedback to achieve the desired therapeutic effect.

[0043] In some cases, the system may measure specific waveforms and intensities of the subject's endogenous EMF. Changes in these EMF characteristics compared to baseline or reference values may be used to detect or monitor various physiological states or medical conditions. The measured EMF data may inform the selection and customization of therapeutic EMF protocols.

[0044] The EMF technology described may enable both diagnostic capabilities through sensitive EMF detection as well as therapeutic interventions via controlled EMF emission. This integrated approach may allow for personalized and adaptive treatments based on a subject's unique EMF profile and response to EMF exposure.

[0045] Embodiments of the present invention disclose a method and a system for diagnosing and treating subjects (either, humans or animals) with EMF, specifically with low frequencies EMF. As used herein, low-frequency EMF is defined as EMF emitted at up to 200 MHz. In some embodiments, the low-frequency EMF used for both diagnosing and treatment is done using ultra-low EMF signals, for example, in the range of 1 V / m- 1 kV / m (electric field intensity). Higher intensities can be used to induce controllable damage. The time interval of exposure is also a parameter to be tuned per application.

[0046] It was found that the EMF of healthy beings (either humans or animals) is different from the EMF of unhealthy beings. This fact may be used for diagnosing an unhealthy state of a subject. It is in the basis of embodiments of the present invention to follow the diagnosis with an EMF-based treatment that may cause reversing / correcting the EMF detectors / sources to healthy signals. In some embodiments, the EMF may be measured using ultrasensitive magnetic or electric sensors placed on or in proximity to the subject. After diagnosing that a deviation from normal or healthy EMF signals / waveforms / spectra was detected, an array of EM emitters may emit EMF that may mimic normal EMF signals / waveforms / spectra or may induce others signals / waveforms / spectra to reverse / correct the EMF back into normal signals.

[0047] In some embodiments, the diagnosis may or may not include diagnosing a specific disease. The method may indicate / identify the medical condition of the subject.Alternatively, the method may simply indicate that the subject is in an “unhealthy state”. In any of the cases, the system may conduct a similar treatment protocol, by radiating the subject by reversing / correcting EM waves. The intensities and waveforms forming a wave of the treatment protocol may be determined based on the measurements of the EMF received from the sensors.

[0048] Some embodiments of the invention are directed to a system in which ELF- EMF sensors are used to measure the EMF of a subject. Then based on the sensor measurements and a desired effect, an EMF signal is generated and applied to the subject or a specific part of the subject (i.e. organ) to induce a potential treatment. Following cessation of signal generation, the sensors will continue to monitor and in a constant feedback loop determine if other or different signals are needed. Both the diagnosis and treatment aspects will require learning sets for baseline of population normal and population disease state and then individualized based on particular subject measurements. Such decisions will require extensive Al and ME to identify the correct EMF signals (vs noise). Additionally, treatment protocols can be based on non-clinical or clinical measurements of biological effects, which will then be corroborated both clinically and individually. This too will require extensive AI / ML to identify subject specific changes and effects. This system can be used to diagnose and treat and / or prevent various disease state as well as being used in an anti-aging or wellness setting.

[0049] As used herein, the term "desired physiological effect" may refer to any beneficial change or outcome in the biological functioning, structure, or condition of a subject's body or specific organs, tissues, or cells resulting from the application of a treatment. This may include, but is not limited to, alterations in metabolic processes, hormone levels, neurotransmitter activity, immune responses, cellular repair mechanisms, gene expression, or any other measurable biological parameter. The desired physiological effect may be aimed at treating a specific medical condition, improving overall health, enhancing performance, or promoting longevity. The effect may be immediate, shortterm, or long-lasting, and may be assessed through various means such as clinicalmeasurements, biomarkers, imaging techniques, or patient-reported outcomes. In the context of this invention, the desired physiological effect is typically one that mimics or replicates the beneficial outcomes of a reference treatment, but achieved through the application of specific electromagnetic field waveforms rather than through conventional therapeutic means.

[0050] As used herein, the term "reference treatment" may refer to a conventional or established therapeutic intervention whose effects the system aims to replicate using electromagnetic field (EMF) waveforms. A reference treatment may include, but is not limited to, the administration of a pharmacologic agent, a physical-device therapy, a psychiatric or neurological intervention, a behavioral or psychological therapy, or a metabolic, geroprotective, longevity, or anti-obesity intervention. The reference treatment serves as a baseline or standard against which the EMF therapy is developed and compared. It is typically a treatment with known physiological effects and established efficacy for a particular condition or desired outcome. The electromagnetic field patterns associated with the application of the reference treatment may be recorded and analyzed to create EMF waveforms that can potentially produce similar therapeutic effects when applied to a subject.

[0051] Reference is now made to Fig. 1 , which is a block diagram depicting a system 100 for providing a therapeutic effect to a subject according to some embodiments of the invention. System 100 may include a computing device 10, illustrated and discussed with respect to Fig. 2, hereinbelow. System 100 may further include one or more low-frequency electromagnetic (LFEM) sensors or low-frequency magnetic field (LFMF) sensors 20A- 20N, one or more energy application units 3OA-3OC, and may optionally include one or more endogenous sensors 25.

[0052] LFEM / LFMF sensors 20A-20N may include any sensor capable of detecting one of: low-frequency electromagnetic fields or low-frequency magnetic fields. In some embodiments, these sensors may comprise ultrasensitive magnetic sensors arranged in an array to detect biomagnetism in a subject, an organ, or a tissue of the subject. The sensorsmay be capable of detecting changes in the LFEM or LFMF of the subject, tissue, or organ with high sensitivity, potentially at the pico-tesla level or below.

[0053] Energy application units 3OA-3OC may include any device capable of emitting EFEM radiation or capable of emitting LFMF towards the subject, tissue, or organ. These energy application units may comprise antennas placed at a known or variable distance from the subject, or electrodes placed in direct contact with the skin of the subject, organ, or tissue. In some embodiments, the energy application units may be connected to one or more signal generators, such as solid-state generators, capable of producing the desired LFEM or LFMF waveforms.

[0054] In some embodiments, the energy application units 3OA-3OC may include magnetic coils capable of providing low-frequency magnetic fields (LFMF) to the subject. These magnetic coils may be designed to generate precise and controlled LFMF waveforms for therapeutic purposes. As shown in Fig. 6B, a LFMF device may comprise a coil structure that allows for the treatment of a subject with a desired LFMF waveform.

[0055] The magnetic coils may be constructed using conductive materials such as copper wire, wound in specific configurations to produce the desired magnetic field characteristics. In some cases, the coils may be air-core coils, while in other implementations, they may include ferromagnetic cores to enhance field strength and directionality.

[0056] The size, shape, and number of turns in the coil may be optimized for different applications, allowing for focused field delivery to specific areas of the subject's body or for broader field coverage. In some embodiments, the coils may be designed to be wearable or easily positioned around the target area of the subject.

[0057] These magnetic coils may be driven by precision current sources controlled by the computing device 10, enabling the generation of LFMF with specific frequencies, intensities, and waveforms. The system may allow for dynamic adjustment of the LFMFparameters based on real-time feedback from the LFEM / LFMF sensors 20A-20N and endogenous sensors 25, facilitating personalized and adaptive treatment protocols.

[0058] The endogenous sensor 25 may be configured to detect various physiological parameters of the subject. This sensor may provide additional data to complement the LFEM / LFMF measurements, allowing for a more comprehensive assessment of the subject's condition.

[0059] Several options for endogenous sensors that may be incorporated into the system include:1. Continuous Glucose Monitoring (CGM) sensors: These sensors can provide realtime measurements of glucose levels in the interstitial fluid, allowing for continuous tracking of blood sugar fluctuations.2. Pulse oximetry sensors: These can monitor oxygen saturation levels in the blood, providing information on respiratory function and overall oxygenation status.3. Heart rate monitors: These sensors can track heart rate variability and other cardiac parameters, which may be relevant for assessing the subject's physiological state.4. Blood pressure sensors: Continuous or intermittent blood pressure monitoring can provide valuable data on cardiovascular function and response to treatment.5. Electroencephalography (EEG) sensors: These can measure brain electrical activity, which may be relevant for neurological applications or assessing cognitive states.6. Electromyography (EMG) sensors: These can monitor muscle activity and may be useful for assessing neuromuscular function or movement disorders.7. Temperature sensors: Continuous body temperature monitoring can provide information on metabolic activity and potential inflammatory responses.8. Cortisol sensors: These can measure cortisol levels in interstitial fluid or sweat, providing data on stress responses and endocrine function.9. Lactate sensors: These can monitor lactic acid levels, which may be relevant for assessing metabolic activity or exercise performance.10. pH sensors: These can measure tissue or blood pH levels, which may be relevant for assessing metabolic states or certain medical conditions.

[0060] These endogenous sensors can provide complementary physiological data to enhance the system's ability to assess the subject's condition and tailor the LFEM or LFMF treatment accordingly. Data collected by any one these systems may be compared to data collected simultaneously to LFEM / LFMF measurements received from any one of LFEM / LFMF sensors 20A-20N. More specifically, the effect of the provision / administration of a treatment to the user may be recorded by both at least one endogenous sensor 25 and at least one LFEM / LFMF sensor 20A-20N.

[0061] The computing device 10 may also compare endogenous signals from the subject, received via the endogenous sensor 25, with the received LFEM or LFMF waveforms. Based on this comparison, the computing device 10 may drive the energy application units 3OA-3OC to emit therapeutic LFEM or LFMF waveforms derived from the received waveforms to achieve a desired therapeutic effect.

[0062] In some embodiments, a waveform of the treatment as shown from the LFEM / LFMF sensor 20A-20N measurements, may be recorded and associated with the treatment. Nonlimiting examples of waveforms recorded during and after the provision of 1 unit of insulin and two units of insulin are shown in Fig. 6B.

[0063] In some embodiments, computing device 10 may receive LFEM or LFMF waveforms from LFEM / LFMF sensors 20A-20N that correspond to a reference treatment, for example, from a database. The computing device 10 may then control the energy application units 3OA-3OC to emit LFEM radiation or LFMF that mimics the therapeutic effect of the reference treatment. The reference treatment may include administration of a pharmacologic agent, a physical-device therapy, a psychiatric, neurological, behavioral or psychological, oncological, inflammatory, allergic intervention, or a metabolic, geroprotective / longevity, or anti-obesity intervention. In the nonlimiting example shown in Fig. 7A LFMF waveforms mimicking 1 unit of insulin and 2 units of insulin were provided using the device shown in Fig. 6B.

[0064] In some embodiments, the LFEM radiation or LFMF emitted by the energy application units 3OA-3OC may have a frequency ranging between 0.1 to 100 Hz, for example, 0.1 10 1 Hz, 1 to 10 Hz, 10 to 50 Hz, 50 to 100 Hz, and any value or range in between. In some embodiments, the EFEM radiation or LFMF emitted by the energy application units 3OA-3OC may have a root-mean-square magnetic-flux density in the range of 0.1 pT to 10 pT, for example, 0.1 to 10 pT, 10 to 100 pT, 100 to 500 pT, 500 pT to 1 nT, 1 to 100 nT, 100 to 500 nT, 500 nT to 1 pT, 1 to 10 pT, and any value or range in between. The LFEM radiation or LFMF radiation may have a nonharmonic frequency waveform. The specific parameters of the emitted fields may be adjusted based on the particular therapeutic effect desired and the individual response of the subject.

[0065] Reference is now made to Fig. 2, which is a block diagram depicting a computing device, which may be included within an embodiment of a system for treating a disease, according to some embodiments.

[0066] Computing device 10 may include a processor or controller 2 that may be, for example, a central processing unit (CPU) processor, a chip or any suitable computing or computational device, an operating system 3, a memory 4, executable code 5, a storage system 6, input devices 7 and output devices 8. Processor 2 (or one or more controllers or processors, possibly across multiple units or devices) may be configured to carry out methods described herein, and / or to execute or act as the various modules, units, etc. More than one computing device 10 may be included in, and one or more computing devices 10 may act as the components of, a system according to embodiments of the invention.

[0067] Operating system 3 may be or may include any code segment (e.g., one similar to executable code 5 described herein) designed and / or configured to perform tasks involving coordination, scheduling, arbitration, supervising, controlling or otherwise managing operation of computing device 10, for example, scheduling execution of software programs or tasks or enabling software programs or other modules or units to communicate. Operating system 3 may be a commercial operating system. It will be notedthat an operating system 3 may be an optional component, e.g., in some embodiments, a system may include a computing device that does not require or include an operating system 3.

[0068] Memory 4 may be or may include, for example, a Random Access Memory (RAM), a read only memory (ROM), a Dynamic RAM (DRAM), a Synchronous DRAM (SD-RAM), a double data rate (DDR) memory chip, a Flash memory, a volatile memory, a non-volatile memory, a cache memory, a buffer, a short term memory unit, a long term memory unit, or other suitable memory units or storage units. Memory 4 may be or may include a plurality of possibly different memory units. Memory 4 may be a computer or processor non-transitory readable medium, or a computer non-transitory storage medium, e.g., a RAM. In one embodiment, a non-transitory storage medium such as memory 4, a hard disk drive, another storage device, etc. may store instructions or code which when executed by a processor may cause the processor to carry out methods as described herein.

[0069] Executable code 5 may be any executable code, e.g., an application, a program, a process, task or script. Executable code 5 may be executed by processor or controller 2 possibly under control of operating system 3. For example, executable code 5 may be an application that may control EMF for treating a disease as further described herein. Although, for the sake of clarity, a single item of executable code 5 is shown in Fig. 2, a system according to some embodiments of the invention may include a plurality of executable code segments similar to executable code 5 that may be loaded into memory 4 and cause processor 2 to carry out methods described herein.

[0070] Storage system 6 may be or may include, for example, a flash memory as known in the art, a memory that is internal to, or embedded in, a micro controller or chip as known in the art, a hard disk drive, a CD-Recordable (CD-R) drive, a Blu-ray disk (BD), a universal serial bus (USB) device or other suitable removable and / or fixed storage unit. Data related to a healthy state of the EMF of a subject or a group of subjects may be in storage system 6 and may be loaded from storage system 6 into memory 4 where it may be processed by processor or controller 2. In some embodiments, some of the componentsshown in Fig. 2 may be omitted. For example, memory 4 may be a non-volatile memory having the storage capacity of storage system 6. Accordingly, although shown as a separate component, storage system 6 may be embedded or included in memory 4.

[0071] Input devices 7 may be or may include any suitable input devices, components or systems, e.g., a detachable keyboard or keypad, a mouse and the like. Output devices 8 may include one or more (possibly detachable) displays or monitors, speakers and / or any other suitable output devices. Any applicable input / output (I / O) devices may be connected to Computing device 1 as shown by blocks 7 and 8. For example, a wired or wireless network interface card (NIC), a universal serial bus (USB) device or external hard drive may be included in input devices 7 and / or output devices 8. It will be recognized that any suitable number of input devices 7 and output device 8 may be operatively connected to Computing device 1 as shown by blocks 7 and 8.

[0072] A system according to some embodiments fof the invention may include components such as, but not limited to, a plurality of central processing units (CPU) or any other suitable multi-purpose or specific processors or controllers (e.g., similar to element 2), a plurality of input units, a plurality of output units, a plurality of memory units, and a plurality of storage units.

[0073] Reference is now made to Fig. 3, which includes a flowchart of a method for treating a disease according to some embodiments of the invention. The method of Fig. 3 may be performed by a system such as system 100 under the supervision of computing device 10 or any other suitable computing device.

[0074] In step 310, the method may include measuring a first LFEM / LFMF waveform of at least one of: a subject, an organ of the subject, a tissue, and a cell. The first LFEM / LFMF waveform may be measured using one or more of LFEM / LFMF sensors 20A-20N. In some embodiments, computing device 10 may, record, analyze, or conduct any required signal analysis procedure to the measured first LFEM / LFMF waveform.

[0075] In some embodiments, the measured first LFEM / LFMF waveform may be filtered and processed using to any suitable method. Some non-limiting examples for filtering methods may include: differential signal collection with two side by side detectors to reduce the impact of distant noise sources low pass and high pass filters and / or low-frequency electromagnetic shielding of sensors from an environment. As should be understood by one skilled in the art, the three examples are non-limiting examples and the invention as a whole is not limited to these three methods.

[0076] In step 320, the method may include receiving at least one previously recordedLFEM / LFMF waveform, associated with a healthy state of: the subject, the organ of the subject, the tissue and / or the cell. In some embodiments, storage system 6 of computing device 10 may include data related to healthy states of various, specific subjects, groups of subjects having at least one common medical condition, specific organs of subjects, healthy tissues, and healthy cells. As used herein medical conditions may include, age, gender, illness, weight, height, and the like. In some embodiments, controller 2 of computing device 10 may receive the healthy state from storage system 6 or from any other database associated with or in communication with computing device 10.

[0077] In step 330, the method may include detecting a change in at least one parameter between the measured LFEM / LFMF waveform and the received LFEM / LFMF waveform. In some embodiments, processor 2 may detect an increase or decrease in the intensity of the LFEM / LFMF in specific waveforms, emission of LFEM / LFMF waveform which are not to be found in the received LFEM / LFMF waveform associated with the healthy state or both.

[0078] In some embodiments, if the detected change is above or below a threshold value (step 340- YES) the method may include, in step 350, irradiating the at least one of: the subject, the organ of the subject, the tissue, and the cell with LFEM / LFMF radiation that causes a measured second LFEM / LFMF waveform, measured after the irradiation to be an LFEM / LFMF waveform associated with the healthy state.

[0079] For example, destructive radiation that may conduct distractive interference with the first LFEM / LFMF waveform. In some embodiments, the destructive radiation may be emitted only at waveforms in which the deviation from healthy LFEM / LFMF waveform was detected. In some embodiments, an additional LFEM / LFMF radiation may be emitted at waveforms where the intensity of the LFEM / LFMF is below the required healthy LFEM / LFMF intensities.

[0080] In another example, LFEM / LFMF radiation at a different waveform may be provided to the subject. The different waveforms may be selected according to the detected change, a diagnosis associated with the detected change, a medical parameter related to the subject and the like.

[0081] In yet another example, the LFEM / LFMF radiation may be provided at the same detected waveform, but at different or similar intensity. In some embodiments, the intensity may be determined based on the detected change, a diagnosis associated with the detected change, a medical parameter related to the subject and the like.

[0082] In yet another example, the LFEM / LFMF radiation may be provided at the same detected waveform and intensity but at different phases. In some embodiments, the phase may be determined based on the detected change, a diagnosis associated with the detected change, a medical parameter related to the subject, and the like.

[0083] In yet another example, the LFEM / LFMF radiation may be provided at the same detected waveform and intensity but in different coherences. For example, the LFEM / LFMF radiation can be coherent or incoherent and the coherency may be determined based on the detected change, a diagnosis associated with the detected change, a medical parameter related to the subject, and the like.

[0084] In yet another example, the LFEM / LFMF radiation may be applied to cause a biological effect that was found via laboratory, non-clinical or clinical experimentation.

[0085] In some embodiments, following the irradiation, a second measuredLFEM / LFMF may be within the limits of the LFEM / LFMF associated with the healthy state.

[0086] The LFEM / LFMF may be provided from array 3OA-3OM of energy application units. In a first nonlimiting example, EMF antennas may emit EM radiation toward the subject, the organ of the subject, the tissue, and the cell. The waveforms and intensities of the emitted EM radiation and the distance of the antennas from the subject may be determined such that the second measured EM field may be within the limits of the EM field associated with the healthy state.

[0087] In another nonlimiting example, LFMF coil may be place around an organ of the subject and may applied LFMF the required LFMF waveform.

[0088] In yet another nonlimiting example, an array of RF electrodes (either bipolar or monopolar electrodes) may be placed in contact with, the skin of the subject, the organ, or the tissue and may provide RF energy to the skin of the subject, the organ or the tissue. The waveforms and intensities of the provided RF energy and the location of the electrodes may be determined such that the second measured EM field may be within the limits of the EM field associated with the healthy state.

[0089] In some embodiments, if the detected change is below a threshold value (step 340-NO) the method may stop in step 345.

[0090] In some embodiments, steps 310-350 may be repeated as many times as necessary until a desired result is achieved. Following LFEM / LFMF radiation, the controller may determine if the desired biological effect, based on measurements received from the sensors, was achieved and if not give further instructions for emission of LFEM / LFMF either increasing intensity or changing frequency or changing waveform.

[0091] Reference is now made to Fig. 4, which is a flowchart of a method of providing a therapeutic effect to a subject, according to some embodiments of the invention.

[0092] In step 410, the method includes receiving one or more LFEM waveforms or one or more LFMF waveforms that correspond to a reference treatment. These waveforms may be received by a computing device from a database or other storage medium containing pre-recorded waveforms associated with various reference treatments.

[0093] In step 420, the method includes controlling at least one energy application unit to emit the one or more EFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment. This step involves the computing device directing the energy application units to generate and apply the specific waveforms received in step 410 to the subject.

[0094] In step 430, the method includes receiving from the LFEM sensor or LFMF sensor one or more LFEM waveforms or LFMF waveforms that correspond to the reference treatment. This step involves capturing the actual waveforms generated in the subject's body or surrounding area in response to the applied treatment.

[0095] These steps allow the system to first identify the appropriate waveforms for a desired treatment, apply those waveforms to the subject, and then measure the resulting waveforms in or around the subject. This process enables the system to mimic the effects of various treatments using LFEM or LFMF, and to verify the effectiveness of the applied waveforms. For example, LFEM or LFMF waveforms may be measured, for example, by sensors 20A-20N during the provision of the desired treatment, using a conventional method, as listed below. In some embodiments, an indication of the result of the desired treatment may be provided using at least one endogenous sensor 25. For example, glucose levels, oxygen levels, heartrate, and the like, may be monitored during the administration of the desired treatment, thereby allowing to identify with part of the waveform recorded by sensors 20A-20N was obtained during the desired treatment. A nonlimiting example for diabetic subject is discussed with respect to Figs. 6 and 7.

[0096] The reference treatment may include administration of a pharmacologic agent, a physical-device therapy, a psychiatric, neurological, behavioral or psychological intervention, oncological, inflammatory, allergic, or a metabolic,geroprotective / longevity, or anti-obesity intervention. By mimicking these treatments with LFEM or LFMF waveforms, the system may provide therapeutic effects without the need for traditional drug administration or invasive procedures.

[0097] Reference is now made to Fig. 5, which is a flowchart of another method of providing a therapeutic effect to a subject according to some embodiments of the invention.

[0098] In step 510, the method includes receiving a reference LFEM or LFMF waveform that corresponds to a reference treatment. This step involves the computing device obtaining a pre-recorded waveform associated with a specific treatment or therapeutic effect from a database or storage medium.

[0099] In step 520, the method includes driving the energy-application unit to emit a therapeutic waveform derived from the reference waveform so as to achieve the desired therapeutic effect. This step involves the computing device controlling the energy-application units to generate and apply a waveform based on the reference waveform received in step 510.

[0100] In step 530, the method includes comparing an endogenous signal from the subject with the reference waveform. This step involves analyzing the subject's physiological response to the applied therapeutic waveform by comparing endogenous signals, which may be captured by one or more endogenous sensors, with the reference waveform. This comparison allows the system to assess the effectiveness of the treatment and potentially make adjustments to the therapeutic waveform as needed.

[0101] These steps enable the system to apply treatments based on known effective waveforms, measure the subject's response through endogenous signals, and compare this response to the expected outcome as represented by the reference waveform. This process allows for personalized and adaptive treatment protocols, potentially improving the efficacy of the LFEM or LFMF therapy.Examples

[0102] The following are nonlimiting examples for the use of the discloses system and method in specific diseases.Diabetes

[0103] In some embodiments, EMF is known to modulate (both raise and lower) blood sugars in models of type 1 and type 2 diabetes. An extremely low-frequency electromagnetic fields (ELF-EMF) may generate a signal between 15-30 minutes that may predict / detect abnormal blood sugars (both hypo and hyperglycemia). A patient is monitored with magnetic sensors and the received data is cross-correlated with existent conventional tools, such as glucose finger sticks or in dwelling glucose sensors, etc. After monitoring multiple events, a data set is created and is used for training. Future events are also used as inputs to machine learning. It is worth underlining that each patient can have specific features in the signals, and, as a result, each individual has to be personally assessed. The approximate range of such signals (intensity, coherence, waveform, polarization) may also be discovered from in vitro or in vivo studies as well.

[0104] If the EM signal predicts an impending high or low blood sugar, an EMF generator may then transmit a waveform that can help lower blood sugars or conversely, raise blood sugar. In some embodiments, the system may mimic the effect of insulin to reduce glucose using sensitive EMF sensors and precise EMF wave generation as discovered in non-clinical or clinical studies.

[0105] The same technique can be performed to discover the effect of glucagon on cells to stimulate an increase in glucose. An EMF signal indicating an impending low blood sugar it can induce an EMF wave in the approximate range of the signal identified in the non-clinical or clinical studies. Then that wave can be modified to achieve an optimal result in that patient. Thus, when the EMF sensors detect an impending rise in blood sugar, the processor may cause the EMF generator to generate the EMF waves corresponding to the insulin effects, conversely if low blood sugar is detected the sensors can signal the EMF generator to create an EMF waves corresponding to the glucagon effects.

[0106] In all embodiments, it may be that everyone will have a personalized response and therefore the feedback mechanism between sensing, treatment and effect needs to beconstantly monitored and treatment protocols adjusted accordingly. Additionally, even within a specific individual there may be changes over time that would need to be learned and applied based on the feedback loop.Specific Insulin study

[0107] Reference is now made to Figs. 6A and 6B, which illustrate aspects of an electromagnetic field (EMF) insulin emission study according to some embodiments of the invention.

[0108] Fig. 6A shows a graph of low-frequency magnetic field (LFMF) waveforms recorded during the provision of 1 unit of insulin and 2 units of insulin. These waveforms were obtained from a diagnostic EMF study performed at Hadassah Medical Center between January and March 2025. The graph displays the characteristic EMF patterns associated with different insulin doses, providing a reference for the EMF insulin mimicking experiments.

[0109] Fig. 6B depicts an LFMF device comprising a coil structure that allows for the treatment of a subject with a desired LFMF waveform. This device was used to emit EMF signals that mimic the effect of insulin administration.

[0110] Reference is now made to Figs. 7A and 7B, which show real glucose measurements taken from Continuous Glucose Monitoring (CGM) during the provision of LFMF waveform to a diabetic subject, and a control measurement, respectively, according to some embodiments of the invention.

[0111] The graph in Fig. 7A displays a distinct glucose curve taken on June 8, 2025, when the LFMF waveforms were applied, while the graph of Fig. 7B shows data from June 16, 2025, which served as a control test.

[0112] On June 8, the subject was disconnected from their insulin pump at 11:00. At 11:37, with a glucose level of approximately 90 mg / dL, the subject consumed 62 grams of grapes (estimated sugar content of 10 grams). From 12:03 to 12:25, an LFMF waveform mimicking 1 unit of insulin was applied. Subsequently, from 12:37 to 12:59, an LFMF waveform mimicking 2 units of insulin was administered.

[0113] The glucose curve for June 8 shows a relatively stable pattern between 90- 100 mg / dL during the period of LFMF exposure (12:00-13:00), despite the prior grape ingestion. This stability suggests that the LFMF waveforms may have produced an insulin-mimetic effect, effectively blunting the expected rise in blood glucose levels.

[0114] In contrast, the control test conducted on June 16 followed a similar protocol but without LFMF treatment. The subject was disconnected from insulin at 11:05, consumed 10 grapes at approximately 11:40, and was reconnected to insulin at 13: 15. The glucose curve for this day demonstrates a more pronounced upward trend following grape ingestion, with levels continuing to rise until insulin reconnection at 13: 15.

[0115] The comparison between these two curves reveals significant differences in glucose responses. The June 8 curve, with LFMF treatment, shows glucose stabilization during the exposure period, while the June 16 control curve exhibits a clear glucose elevation during the same timeframe.

[0116] These results suggest that the LFMF waveforms applied on June 8 may have effectively mimicked the action of insulin, stabilizing blood glucose levels in a manner similar to exogenous insulin administration. The timing and magnitude of the glucose response observed on June 8 were consistent with the action of approximately 1.5-2 units of rapid-acting insulin.

[0117] This real-world data from CGM measurements provides compelling evidence for the potential of LFMF waveforms to mimic insulin effects in managing blood glucose levels. However, it is important to note that this represents a single case study, and further research with larger sample sizes would be necessary to validate these findings and establish the broader applicability and safety of this approach in diabetes management.Epilepsy

[0118] Epilepsy is a neurological disorder characterized by spikes in electrical activity in the brain cortex which can result in a seizure. Such spikes in electrical activity can be measured by EEG measurements. Such measurements may also be used to predicta seizure as the brain’s electrical activity begins to become more active prior to an attack. It is also useful to note that epileptic seizures are often preceded by an aura which is predictive of an impending seizure. It is thus reasonable to assume that changes in EMF may be detected by the ELF-EMF sensors, especially when compared to a database of normal subjects and / or a baseline in the patient and therefore also be used to predict an impending seizure.

[0119] It has also been found that repetitive transmagnetic stimulation for the treatment of drug-resistant epilepsy has been shown to reduce seizure frequency.

[0120] It has also been found that when using a magnetoencephalographic brain measurement device, a seizure was recorded and “utilizing the same intensity and frequency of magnetic field to the presumed epileptic foci to successfully attenuate seizure activity.

[0121] Therefore, utilizing the ELF-EMF sensors to detect EMF activity that may predict a seizure, which may then cause the generation of an EMF field that would emulate the impending seizure or apply a specific frequency / waveform that has been shown to inhibit neuronal firing as discovered in in-vitro or in-vivo testing in order to prevent an epileptic seizure. Such activities would also be based on comparing normal times or subjects versus those suffering from epilepsy and then a feedback loop to di scover which EMF treatments are most effective.Cancer

[0122] It has been well established that EMF can both cause and treat various cancers. In this iteration, the sensors would constantly monitor the subject for deviations from normal age-adjusted cohorts or normal cohorts and or detect perturbations from baseline that might indicate the onset or presence of cancerous tissues which would emit different EM signals that normal cells / organ / body. In some embodiments, a first database comprising EMF baselines of healthy persons may be compared to the detected EMF to determine if the subject is suffering from cancer. Additionally, the detected EMF may becompared to a second database comprising EMF of detected and diagnosed cancer patients in order to find similarities between the detected EMF and the previously stored EMF. The first and second databases may be gathered during a training phase conducted on multiple patients / healthy persons. Additionally, EMF measurements of in vitro cancer cells / tissues may also be measured and compared to normal to discover the EMF signature of cancer. EMF irradiation in vitro or in vivo may also be used to discover effective treatment protocols.

[0123] In some embodiments, once an abnormal EMF is detected, then a variety of EMF waves may be used to treat it. Such methodologies may mimic the abnormal EMF with increased amplitude to destroy abnormal tissues. Other approaches may include cancer EMF counter-phase irradiation, or non-coherent EMF or EMF (coherent or noncoherent) that was found to inhibit that cancer type in non-clinical studies.Wellness / Anti-aging

[0124] Another proposed application may be in the field of wellness or anti-aging. For example one may measure the EMF signals of a cohort of juvenile, young or athletic population and compare their EMF to a more age advanced / elderly population. If differences can be found, then EMF signals that mimic those of the younger / healthier population is administered to the more age advanced subjects and over time, the EMF of those subjects may improve over time and reflect a younger / healthier state. As in the other examples, both comparison to a desired cohort effect as well as individual changes would be used in a AI / ML based feedback loop.

[0125] Unless explicitly stated, the method embodiments described herein are not constrained to a particular order or sequence. Furthermore, all formulas described herein are intended as examples only and other or different formulas may be used. Additionally, some of the described method embodiments or elements thereof may occur or be performed at the same point in time.

[0126] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents may occur to those skilled in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.

[0127] Various embodiments have been presented. Each of these embodiments may of course include features from other embodiments presented, and embodiments not specifically described may include various features described herein.

Claims

CLAIMS1. A system for providing a therapeutic effect to a subject, comprising: at least one energy application unit, configured to emit one of: a low-frequency electromagnetic (LFEM) radiation or configured to emit a low-frequency magnetic field (LFMF); and a controller configured to: receive one or more EFEM waveforms or one or more FLMF waveforms that correspond to a reference treatment; and control the at least one energy application unit to emit the one or more LFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment.

2. The system of claim 1, further comprising an LFEM sensor or LFMF sensor, wherein the controller is further configured to receive from the LFEM sensor or LFMF sensor one or more LFEM waveforms or LFMF waveforms that correspond to the reference treatment.

3. The system of claim 2, wherein the controller is further configured to: compare an endogenous signal from the subject with the received one or more LFEM waveforms or LFMF waveforms, and wherein controlling the at least one energy application unit comprises driving the energy-application unit to emit one or more therapeutic LFEM waveforms or LFMF waveforms derived from the one or more received LFEM waveforms or LFMF waveforms so as to achieve a desired therapeutic effect.

4. The system of any one of claims 1 to 3, wherein the reference treatment is selected from: an administration of: a pharmacologic agent, a physical-device therapy, a psychiatric, neurological, behavioral or psychologic intervention, oncological, inflammatory, allergic, and a metabolic, geroprotective / longevity, or anti-obesity intervention.

5. The system of claim 4, wherein the pharmacologic agent is selected from the group consisting of: (i) an insulin or insulin analogue; (ii) a glucagon-like peptide- 1 (GLP-1) receptor agonist; (iii) a sodium-glucose co-transporter-2 (SGLT-2) inhibitor; (iv) a P- adrenergic antagonist; (v) a serotonergic or dopaminergic neuromodulator; (vi) a cytotoxic or targeted chemotherapeutic compound; (vii) an agent that enhances mitochondrial function or biogenesis, selected from NAD+precursors, sirtuin activators, pyrroloquinoline quinone (PQQ), coenzyme Q10, or a PGC- la up-regulator; (viii) an mTOR-pathway modulator or AMPK activator, including rapamycin, metformin, or analogues thereof; and any pharmaceutically acceptable combinations thereof.

6. The system of any one of claims 1 to 5, wherein the LFEM radiation or LFMF radiation has a frequency ranging between 0.1 to 100 Hz.

7. The system of any one of claims 1 to 6, wherein the LFEM radiation or LFMF radiation has a nonharmonic frequency waveform.

8. The system of any one of claims 1 to 7, wherein the LFEM radiation or LFMF radiation has a root-mean-square magnetic-flux density in the range of 0.1 pT to 10 pT.

9. The system of any one of claims 1 to 8, wherein the at least one energy application unit comprises an LFEM radiation generator and at least one LFEM radiation antenna.

10. The system of any one of claims 1 to 8, wherein the at least one energy application unit comprises a power source and at least one magnetic coil.I L A method for providing a therapeutic effect to a subject, comprising: receiving one or more low-frequency electromagnetic (LFEM) waveforms or one or more low-frequency magnetic field (LFMF) waveforms that correspond to a reference treatment; and controlling at least one energy application unit to emit the one or more LFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment.

12. The method of claim 11, further comprising receiving from an LFEM sensor or LFMF sensor one or more LFEM waveforms or LFMF waveforms that correspond to the reference treatment.

13. The method of claim 12, further comprising: comparing an endogenous signal from the subject with the received one or more LFEM waveforms or LFMF waveforms; and wherein controlling the at least one energy application unit comprises driving the energy application unit to emit one or more therapeutic LFEM waveforms or LFMF waveforms derived from the one or more received LFEM waveforms or LFMF waveforms so as to achieve a desired therapeutic effect.

14. The method of any one of claims 11 to 13, wherein the reference treatment is selected from: an administration of a pharmacologic agent, a physical-device therapy, a psychiatric, neurological, behavioral or psychologic intervention, oncological, inflammatory, allergic, and a metabolic, geroprotective / longevity, or anti-obesity intervention.

15. The method of claim 14, wherein the pharmacologic agent is selected from the group consisting of: (i) an insulin or insulin analogue; (ii) a glucagon-like peptide- 1 (GLP-1) receptor agonist; (iii) a sodium-glucose co-transporter-2 (SGLT-2) inhibitor; (iv) a P-adrenergic antagonist; (v) a serotonergic or dopaminergic neuromodulator; (vi) a cytotoxic or targeted chemotherapeutic compound; (vii) an agent that enhances mitochondrial function or biogenesis, selected from NAD+precursors, sirtuin activators, pyrroloquinoline quinone (PQQ), coenzyme Q10, or a PGC- la up-regulator; (viii) an mTOR-pathway modulator or AMPK activator, including rapamycin, metformin, or analogues thereof; and any pharmaceutically acceptable combinations thereof.

16. A system for producing a desired therapeutic effect in a subject, comprising: at least one energy-application unit configured to emit low-frequency electromagnetic radiation (LFEM) or configured to emit a low-frequency magnetic field (LFMF); anda controller configured to receive a reference LFEM or LFMF waveform that corresponds to a reference treatment and drive the energy-application unit to emit a therapeutic waveform derived from the reference waveform so as to achieve the desired therapeutic effect.

17. The system of claim 16, wherein the controller is further configured to compare an endogenous signal from the subject with the reference waveform.

18. The system of claim 16 or claim 17, wherein the endogenous signal is received from at least one of: Continuous Glucose Monitoring (CGM), pulse oximetry, heart rate monitoring, blood pressure monitoring, electroencephalography (EEG), electromyography (EMG), temperature sensing, cortisol sensing, lactate sensing, and pH sensing.

19. The system of any one of claims 16 to 18, wherein the reference treatment is selected from: an administration of a pharmacologic agent, a physical-device therapy, a psychiatric, neurological, behavioral or psychologic intervention, and a metabolic, oncological, inflammatory, allergic, geroprotective / longevity, or anti-obesity intervention.

20. A non-transitory computer readable storage medium storing a set of instructions for causing a computer to: receive one or more LFEM waveforms or one or more FLMF waveforms that correspond to a reference treatment; and control at least one energy application unit to emit the one or more LFEM waveforms or the one or more LFMF waveforms to mimic the therapeutic effect of the reference treatment.

21. A method of treating subject, comprising: measuring a first LFEM waveform or a first LFMF waveform of at least one of: a subject, an organ of the subject, a tissue, and a cell; receiving at least one previously recorded LFEM waveform or LFMF waveform, associated with a healthy state at least one of: the subject, the organ of the subject, the tissue, and the cell;detecting a change in at least one parameter between the measured LFEM waveform or LFMF waveform and the received EFEM waveform or LFMF waveform; and if the change is greater than a threshold value, irradiating the at least one of: the subject, the organ of the subject, the tissue, and the cell with LFEM waveform or LFMF waveform that causes a measured second LFEM waveform or LFMF waveform, measured after the irradiation to be an LFEM waveform or LFMF waveform associated with a desired physiological effect.

Images